From Lab to Market: Navigating Uncertainty Custom Case Solution & Analysis

Evidence Brief: From Lab to Market

Financial Metrics

• Total grant funding received: 2.2 million USD from federal sources.
• Remaining cash runway: 450,000 USD, estimated to last 9 months at current burn rates.
• Estimated market size for high-purity applications: 180 million USD annually.
• Estimated market size for industrial coatings: 1.2 billion USD annually.
• Licensing offer from incumbent: 500,000 USD upfront with 3 percent royalty on net sales.

Operational Facts

• Current production capacity: 5 kilograms per month in a university laboratory setting.
• Industrial scale requirement: 500 kilograms per month for commercial viability.
• Patent status: Provisional patent filed; 11 months remaining until international filing deadline.
• Staffing: 3 post-doctoral researchers and 1 principal investigator.
• Geography: Research conducted in a Tier 1 US research university.

Stakeholder Positions

• Dr. Elena Rodriguez (Principal Investigator): Desires to see the technology reach maximum societal impact but lacks business experience.
• Director Marcus Thorne (University TTO): Prefers an immediate licensing deal to mitigate risk and generate immediate returns for the university.
• Sarah Chen (Venture Capitalist): Interested in a Series A round but demands a 40 percent equity stake and a professional CEO.
• ChemCorp Executive Team: Views the technology as a defensive acquisition to protect their existing product line.

Information Gaps

• Manufacturing cost at a scale of 500 kilograms per month remains unproven.
• Competitor response time to a new market entrant is not quantified.
• The specific regulatory requirements for the medical application path are not fully mapped.

Strategic Analysis

Core Strategic Question

• Should the venture pursue a low-risk licensing model with an incumbent or build an independent entity to capture high-margin niche markets?

Structural Analysis

Value Chain Analysis

The primary bottleneck exists in the transition from primary research to specialized manufacturing. The university lab handles R and D effectively, but the venture lacks the infrastructure for outbound logistics and marketing. Capturing value requires moving downstream into specialized applications rather than remaining a raw material supplier.

Jobs-to-be-Done

Industrial customers do not want a new polymer; they want to reduce the failure rate of coatings in extreme environments. The medical segment seeks to eliminate post-surgical infections. The medical application solves a high-consequence problem, allowing for significant price premiums compared to the industrial commodity market.

Strategic Options

Option 1: Exclusive Licensing to ChemCorp

• Rationale: Immediate monetization and transfer of scaling risks to a partner with existing infrastructure.
• Trade-offs: Loss of long-term upside and no control over whether the technology is actually commercialized or shelved.
• Resource Requirements: Legal counsel for contract finalization.

Option 2: Venture-Backed Spin-off (Medical Focus)

• Rationale: Focuses on high-margin, low-volume production that fits current lab capabilities while scaling.
• Trade-offs: High execution risk and significant equity dilution.
• Resource Requirements: 5 million USD Series A funding and a professional management team.

Option 3: Bootstrapped Joint Development (Industrial Focus)

• Rationale: Uses customer pre-payments to fund scaling without giving up equity.
• Trade-offs: Slower market entry and high risk of being outpaced by capitalized competitors.
• Resource Requirements: Two committed industrial partners for pilot programs.

Preliminary Recommendation

Pursue Option 2. The unit economics of the medical segment justify the capital intensity of a spin-off. Licensing to ChemCorp likely results in the technology being used only to protect their current portfolio, limiting its market reach.

Implementation Roadmap

Critical Path

• Month 1: Secure exclusive option for the patent from the University TTO.
• Month 2: Recruit a CEO with experience in medical device commercialization.
• Month 3-4: Close 5 million USD Series A funding round.
• Month 5-8: Establish a dedicated ISO-certified manufacturing facility.
• Month 9: Initiate regulatory filing for the primary medical application.

Key Constraints

• Talent Acquisition: The venture requires specialized engineers who understand both polymer science and medical regulatory standards.
• Scaling Friction: Moving from 5 kilograms to 500 kilograms often reveals chemical instabilities that are not present at lab scale.

Risk-Adjusted Implementation Strategy

The strategy assumes a 12-month window for regulatory approval. To mitigate the risk of delay, the venture will simultaneously pursue a non-regulated industrial application as a secondary revenue stream. This provides a fallback if the medical path encounters unforeseen hurdles. Contingency funds of 20 percent will be reserved from the initial funding round to cover unexpected R and D iterations during the scaling phase.

Executive Review and BLUF

BLUF

Reject the licensing offer from ChemCorp. The venture should spin off as an independent entity focused on the medical device market. While licensing offers immediate cash, it undervalues the technology by a factor of ten and risks internal shelving by the incumbent. The medical segment allows for a smaller initial production footprint while generating the margins necessary to sustain high R and D costs. Success depends on immediate recruitment of a commercial leader to bridge the gap between scientific discovery and market execution. Execute a Series A raise within 90 days to avoid the cash cliff.

Dangerous Assumption

The analysis assumes that the 180 million USD medical market is accessible without a 5-year clinical trial period. If the regulatory path is longer than 24 months, the venture will exhaust its Series A funding before reaching commercial revenue.

Unaddressed Risks

• Intellectual Property Leakage: The move from a university lab to a private facility creates a window where trade secrets may be vulnerable before full patent protection is granted.
• Founder Friction: Dr. Rodriguez may struggle to cede operational control to a professional CEO, leading to leadership paralysis during critical scaling phases.

Unconsidered Alternative

The team did not evaluate a sub-licensing model where the venture retains rights to the medical field while licensing the industrial applications to ChemCorp. This would provide immediate non-dilutive capital to fund the high-margin medical pursuit while offloading the low-margin scaling burden.

VERDICT: APPROVED FOR LEADERSHIP REVIEW